| Literature DB >> 35321185 |
Ming-Feng Zhuo1, Ke-Lian Zhang2, Xue-Bin Shen3, Wen-Can Lin1, Bin Hu1, Hua-Peng Cai1, Gang Huang4.
Abstract
BACKGROUND: Myocardial infarction is one of the most common types of coronary heart disease. It is mainly caused by the rupture of coronary atherosclerotic plaque, which leads to platelet agglutination and thrombosis. The occlusion of coronary arteries and vessels leads to insufficient myocardial blood supply, subsequently causing cardiac interstitial fibrosis, gradual enlargement of ventricles, and heart failure, which affects the quality of life and safety of patients. AIM: To investigate the effects of emergency percutaneous interventional therapy (PCI) and delayed stenting in acute myocardial infarction with high thrombotic load and identify factors related to major adverse cardiovascular events (MACE).Entities:
Keywords: Adverse cardiovascular events; Coronary thrombosis; Emergency; Myocardial infarction; Percutaneous coronary intervention; Treatment delay
Year: 2022 PMID: 35321185 PMCID: PMC8895172 DOI: 10.12998/wjcc.v10.i7.2106
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Comparison of thrombolysis in myocardial infarction flow grades and thrombolysis in myocardial infarction myocardial perfusion grade grading after stent implantation between the two groups, n (%)
|
|
|
|
|
|
| TIMI flow grades | -2.302 | 0.021 | ||
| 0 degree | 0 (0) | 0 (0) | ||
| 1 degree | 2 (2.17) | 6 (8.33) | ||
| 2 degree | 24 (26.09) | 26 (36.11) | ||
| 3 degree | 66 (71.74) | 40 (55.56) | ||
| TMPG grading | -1.836 | 0.066 | ||
| 0 degree | 0 (0.00) | 0 (0.00) | ||
| 1 degree | 3 (3.26) | 8 (11.11) | ||
| 2 degree | 28 (30.43) | 25 (34.72) | ||
| 3 degree | 61 (66.30) | 39 (54.17) |
TIMI: Thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade.
Comparison of ST segment fall rate at 90 min after percutaneous coronary intervention, n (%)
|
|
|
|
|
| Delayed Group | 92 | 76 (82.61) | 16 (17.39) |
| Immediate group | 72 | 56 (77.78) | 16 (22.22) |
|
| 0.600 | ||
|
| 0.438 | ||
Single factor analysis of major adverse cardiovascular events occurrence
|
|
|
|
|
|
| Age (yr) | 63.9 ± 7.7 | 65.0 ± 8.1 | -0.669 | 0.504 |
| BMI (kg/m2) | 24.1 ± 2.0 | 23.8 ± 2.4 | 0.628 | 0.531 |
| HR (times/min) | 91.6 ± 8.2 | 93.0 ± 7.6 | -0.888 | 0.376 |
| Number of implanted stents | 1.85 ± 0.45 | 1.98 ± 0.50 | -1.292 | 0.198 |
| Gender | 1.002 | 0.317 | ||
| Male | 18 (62.07) | 70 (51.85) | ||
| Female | 11 (37.93) | 65 (48.15) | ||
| Diabetes | 4.314 | 0.038 | ||
| Yes | 9 (31.03) | 20 (14.81) | ||
| No | 20 (68.97) | 115 (85.19) | ||
| Hypertension | 3.758 | 0.053 | ||
| Yes | 13 (44.83) | 36 (26.67) | ||
| No | 16 (55.17) | 99 (73.33) | ||
| Hyperlipidemia | 1.851 | 0.174 | ||
| Yes | 18 (62.07) | 65 (48.15) | ||
| No | 11 (37.93) | 70 (51.85) | ||
| Smoking | 1.851 | 0.174 | ||
| Yes | 11 (37.93) | 34 (25.19) | ||
| No | 18 (62.07) | 101 (74.81) | ||
| Infarct related blood vessel | 5.729 | 0.126 | ||
| Anterior descending branch | 16 (55.17) | 43 (31.85) | ||
| Circumflex | 4 (13.79) | 29 (21.48) | ||
| Left main stem | 2 (6.9) | 11 (8.15) | ||
| Right coronary artery | 7 (24.14) | 52 (38.52) | ||
| Killp rating | 0.805 | 0.370 | ||
| 1-2 degree | 22 (75.86) | 112 (82.96) | ||
| 3-4 degree | 7 (24.14) | 23 (17.04) | ||
| Use ACEI | 1.277 | 0.258 | ||
| Yes | 18 (62.07) | 98 (72.59) | ||
| No | 11 (37.93) | 37 (27.41) | ||
| Use beta blockers | 0.818 | 0.366 | ||
| Yes | 21 (72.41) | 108 (80.00) | ||
| No | 8 (27.59) | 27 (20.00) | ||
| TIMI grading | 6.046 | 0.014 | ||
| 3 degree | 13 (44.83) | 93 (68.89) | ||
| < 3 degree | 16 (55.17) | 42 (31.11) | ||
| TMPG grading | 3.861 | 0.049 | ||
| 3 degree | 13 (44.83) | 87 (64.44) | ||
| < 3 degree | 16 (55.17) | 48 (35.56) | ||
| Timing of stent implantation | 6.683 | 0.010 | ||
| Immediately | 19 (65.52) | 53 (39.26) | ||
| Extension | 10 (34.48) | 82 (60.74) | ||
| Intraoperative use of tirofiban | 4.599 | 0.032 | ||
| Yes | 17 (58.62) | 105 (77.78) | ||
| No | 12 (41.38) | 30 (22.22) | ||
| CK-MB peak (U/L) | 226.4 ± 44.1 | 218.0 ± 40.8 | 0.992 | 0.323 |
| WBC (109/L) | 12.63 ± 2.01 | 11.18 ± 1.80 | 3.854 | 0.000 |
| N (109/L) | 9.80 ± 1.14 | 15.13 ± 0.63 | -35.022 | 0.000 |
| RDW | 13.54 ± 2.08 | 12.61 ± 1.86 | 2.392 | 0.018 |
| UA (μmol/L) | 368.1 ± 42.2 | 340.7 ± 38.5 | 3.418 | 0.001 |
| hs-CRP (mg/L) | 10.58 ± 2.81 | 8.62 ± 2.51 | 3.734 | 0.000 |
MACE: Major adverse cardiovascular events; BMI: Body mass index; HR: Heart rate; ACEI: Angiotensin-converting enzyme inhibitor; TIMI: Thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade; WBC: White blood cells; N: Neutrophils; RDW: Red blood cell distribution width; UA: Uric acid; hs-CRP: High-sensitivity C-reactive protein.
Logistic regression analysis of factors affecting major adverse cardiovascular events occurrence
|
|
|
|
|
|
|
| |
| Diabetes | 0.471 | 0.288 | 2.675 | 0.166 | 1.602 | 0.911 | 2.816 |
| TIMI rating | -0.552 | 0.24 | 5.290 | 0.033 | 0.576 | 0.360 | 0.922 |
| TMPG rating | -0.464 | 0.317 | 2.142 | 0.247 | 0.629 | 0.338 | 1.170 |
| Timing of stent implantation | 0.758 | 0.336 | 5.089 | 0.036 | 2.134 | 1.105 | 4.123 |
| Intraoperative use of tirofiban | -0.392 | 0.15 | 6.830 | 0.011 | 0.676 | 0.504 | 0.907 |
| WBC | 0.608 | 0.275 | 4.888 | 0.042 | 1.837 | 1.071 | 3.149 |
| N | 0.418 | 0.336 | 1.548 | 0.304 | 1.519 | 0.786 | 2.935 |
| RDW | 0.577 | 0.22 | 6.879 | 0.009 | 1.781 | 1.157 | 2.741 |
| UA | 0.718 | 0.484 | 2.201 | 0.243 | 2.050 | 0.794 | 5.294 |
| hs-CRP | 0.466 | 0.215 | 4.698 | 0.045 | 1.594 | 1.046 | 2.429 |
MACE: Major adverse cardiovascular events; TIMI: Thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade; WBC: White blood cells; N: Neutrophils; RDW: Red blood cell distribution width; UA: Uric acid; hs-CRP: High-sensitivity C-reactive protein.